Raymond James initiates coverage of Benitec Biopharma with outperform rating, $14 target
BNTC•Raymond James initiated coverage of Benitec Biopharma with an outperform rating and a $14 target price.
Related News
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug
ZYME•
Norfolk Southern: TD Cowen raises target price to $379 from $376
NSC•
Wyndham Hotels & Resorts: Deutsche Bank raises target price to $105 from $104
WH•
Prudential Financial target price cut to $102 from $105 by Deutsche Bank
PRU•